Ebek voluntarily recalls Liviro3.Ebek announced Jan. 19 that it is conducting a voluntary nationwide recall of the company's supplement product sold under the name Liviro3. The company has been informed that lab analysis by FDA FDA
Food and Drug Administration
n.pr See Food and Drug Administration.
n.pr the abbreviation for the Food and Drug Administration. of Liviro3 samples found the product contains tadalafil, an FDA-approved drug used to treat erectile dysfunction Erectile Dysfunction Definition
Erectile dysfunction (ED), formerly known as impotence, is the inability to achieve or maintain an erection long enough to engage in sexual intercourse. (ED), making Liviro3 an unapproved un·ap·proved
Not approved or sanctioned: an unapproved vaccine; an unapproved protest march. drug, the agency stated in a release.
FDA advised that this poses a threat to consumers because tadalafil may interact with nitrates found in some prescription drugs and may lower blood pressure to dangerous levels.
According to FDA, consumers with diabetes, high blood pressure, high cholesterol Cholesterol, High Definition
Cholesterol is a fatty substance found in animal tissue and is an important component to the human body. It is manufactured in the liver and carried throughout the body in the bloodstream. , or heart disease often take nitrates. FDA advises that tadalafil, may cause side effects Side effects
Effects of a proposed project on other parts of the firm. , such as headaches and flushing.
The recalled Liviro3 is sold in 10-tablet boxes or 20-tablet plastic bottles. The product label warns consumers with high blood pressure not to ingest in·gest
tr.v. in·gest·ed, in·gest·ing, in·gests
1. To take into the body by the mouth for digestion or absorption. See Synonyms at eat.
2. the product but does not state it contains tadalafil.
Consumers who have Liviro3 in their possession should stop using it immediately and contact their physician if they experienced any problem that may be related to taking this product.
No illnesses have been reported to the Company to date in connection with this product.
The public is encouraged to submit a report of any serious adverse events that occur with the use of Liviro3 to FDA's MedWatch Adverse Event Reporting program online www.fda.gov/MedWatch/report.htm ], by phone [800-FDA-1088], or by returning the post-age-paid FDA form 3500 [which may be downloaded from www.fda.gov/MedWatch/getforms.htm] by mail [to MedWatch, 5600 Fishers Lane, Rockville, MD 20852-9787] or fax [800-FDA-0178].